What is HC Wainwright’s Estimate for MIST FY2028 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Research analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.38 per share for the year, down from their prior forecast of $0.43. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share.

A number of other equities analysts have also recently issued reports on MIST. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, July 14th. Wells Fargo & Company lowered their price objective on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Finally, Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Milestone Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Milestone Pharmaceuticals Trading Down 11.4%

NASDAQ MIST opened at $1.12 on Thursday. The company has a market cap of $140.06 million, a price-to-earnings ratio of -1.65 and a beta of 0.98. Milestone Pharmaceuticals has a 52 week low of $1.00 and a 52 week high of $3.06. The business has a 50 day moving average price of $1.24 and a 200-day moving average price of $1.53. The company has a quick ratio of 9.09, a current ratio of 9.18 and a debt-to-equity ratio of 1.61.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.82 million.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MIST. Strategic Family Wealth Counselors L.L.C. bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth $25,000. Eaton Financial Holdings Company LLC bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at about $26,000. Welch & Forbes LLC bought a new position in shares of Milestone Pharmaceuticals during the first quarter valued at about $30,000. Bank of America Corp DE lifted its position in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in Milestone Pharmaceuticals during the fourth quarter worth about $42,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals News Summary

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: CARDAMYST coverage expanded to more than 50% of commercially insured U.S. lives, up substantially from approximately 25% earlier in the year. The company also reported more than 800 prescribers and 1,500 prescriptions through June 30, suggesting increasing market access. Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: The Phase 3 ReVeRA-301 trial of etripamil for atrial fibrillation with rapid ventricular rate is open with clinical sites activated, creating a potential second indication and larger commercial opportunity. Milestone Pharmaceuticals Reports Q2 2026 Results
• Positive Sentiment: Milestone ended the quarter with $170.6 million in cash, cash equivalents and short-term investments, which management expects will fund operations into the second half of 2027.
• Neutral Sentiment: Regulatory reviews for PSVT applications in Europe and China remain ongoing, with a potential European decision expected in the first half of 2027. The earnings call provided additional discussion of the commercial launch and development pipeline. Milestone Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter EPS was a loss of $0.21, missing the consensus loss estimate of $0.20, while revenue of $0.56 million fell short of the $0.82 million forecast. Milestone Pharmaceuticals Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Net loss widened to $28.6 million from $13.0 million a year earlier, driven largely by selling, general and administrative expenses that more than doubled to $22.6 million as CARDAMYST commercialization ramped up. Product revenue remained modest at $0.6 million, raising concerns about adoption and the pace of revenue growth. Milestone Pharmaceuticals Shares Tumble After Q2 Earnings Miss

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.